6533b854fe1ef96bd12af31e

RESEARCH PRODUCT

Childhood supratentorial ependymomas with YAP1-MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features

Clemens SommerThomas RüdigerJörg FaberVerena DreschmannStéphanie PugetBernhard ErdlenbruchB BernbeckEvelyn DörnerDominik SchneiderSung Hye ParkAlexandra RussoFelipe AndreiuoloSelim CorbaciogluMartina Messing-jüngerTorsten PietschStephanie Theresa JüngerMarco PrinzMarkus J. RiemenschneiderMarkus BergmannAndreas WahaIrene SlavcChristine HaberlerRupert HandgretingerMiriam Van BuirenAntonia JakovcevicSven ArmbrustAlfred LeipoldHarald ReinhardArnault Tauziède-espariatDieter KörholzKlaus KuchelmeisterMartina RoseJohann LorenzenMartin EbingerManuela NeumannJelena RoganovićPascale VarletTill AckerElke HattingenVolkmar HansJacques Grill

subject

0301 basic medicineEpendymomaSanger sequencingPathologymedicine.medical_specialtybusiness.industryGeneral NeuroscienceSupratentorial NeoplasmLocus (genetics)medicine.diseaseMolecular Inversion ProbePathology and Forensic Medicine03 medical and health sciencessymbols.namesake030104 developmental biology0302 clinical medicineImmunophenotypingmedicinesymbolsHistopathologyNeurology (clinical)medicine.symptombusinessAnaplasia030217 neurology & neurosurgery

description

Ependymoma with YAP1-MAMLD1 fusion is a rare, recently described supratentorial neoplasm of childhood, with few cases published so far. We report on 15 pediatric patients with ependymomas carrying YAP1-MAMLD1 fusions, with their characteristic histopathology, immunophenotype and molecular/cytogenetic, radiological and clinical features. The YAP1-MAMLD1 fusion was documented by RT-PCR/Sanger sequencing, and tumor genomes were studied by molecular inversion probe (MIP) analysis. Significant copy number alterations were identified by GISTIC (Genomic Identification of Significant Targets in Cancer) analysis. All cases showed similar histopathological features including areas of high cellularity, presence of perivascular pseudo-rosettes, small to medium-sized nuclei with characteristic granular chromatin and strikingly abundant cells with dot-like cytoplasmic expression of epithelial membrane antigen. Eleven cases presented features of anaplasia, corresponding to WHO grade III. MRI showed large supratentorial multinodular tumors with cystic components, heterogeneous contrast enhancement, located in the ventricular or periventricular region. One of two variants of YAP1-MAMLD1 fusions was detected in all cases. The MIP genome profiles showed balanced profiles, with focal alterations of the YAP1 locus at 11q22.1-11q21.2 (7/14), MAMLD1 locus (Xp28) (10/14) and losses of chromosome arm 22q (5/14). Most patients were female (13/15) and younger than 3 years at diagnosis (12/15; median age, 8.2 months). Apart from one patient who died during surgery, all patients are alive without evidence of disease progression after receiving different treatment protocols, three without postoperative further treatment (median follow-up, 4.84 years). In this to date, largest series of ependymomas with YAP1-MAMLD1 fusions we show that they harbor characteristic histopathological, cytogenetic and imaging features, occur mostly in young girls under 3 years and are associated with good outcome. Therefore, this genetically defined neoplasm should be considered a distinct disease entity. The diagnosis should be confirmed by demonstration of the specific fusion. Further studies on large collaborative series are warranted to confirm our findings.

https://doi.org/10.1111/bpa.12659